METHOD OF PHYSICOCHEMICALLY PRODUCING GLYCOGEN AND GLYCOGEN OBTAINED BY THE SAME
    1.
    发明申请
    METHOD OF PHYSICOCHEMICALLY PRODUCING GLYCOGEN AND GLYCOGEN OBTAINED BY THE SAME 审中-公开
    物理化学生产由其获得的GLYCOGEN和GLYCOGG的方法

    公开(公告)号:US20080262217A1

    公开(公告)日:2008-10-23

    申请号:US12145256

    申请日:2008-06-24

    IPC分类号: C08B31/00

    CPC分类号: C08B37/0009

    摘要: A method of producing glycogen is provided. The method comprises the step of heat- and pressure-treating a sugar-containing material under acidic conditions. The sugar-containing material is a polysaccharide or an oligosaccharide. Alternatively, the sugar-containing material is a plant material selected from the group consisting of Panax notoginseng, Yun Nan San-chi powder (trademark), Panax ginseng, wheat flour, soybean, soy flour, shiitake, and coffee extract residue. Representatively, the glycogen includes a molecule having a molecular weight of 10,000 or less. The glycogen has a specific rotation of [α]D+197° and anomeric proton peaks at 5.37 ppm and 4.95 to 5.33 ppm in 1H NMR spectra.

    摘要翻译: 提供了制备糖原的方法。 该方法包括在酸性条件下对含糖材料进行加热和加压处理的步骤。 含糖材料是多糖或寡糖。 或者,含糖材料是选自三七,云南三奇粉(商标),人参,小麦粉,大豆,大豆粉,香菇和咖啡提取物残渣的植物材料。 代表性地,糖原包括分子量为10,000以下的分子。 在1 H NMR光谱中,糖原具有α-D + 197°的比旋光度和5.37ppm和4.95- 5.33ppm的异质质子峰。

    Process for physicochemically producing glycogen and glycogen obtained thereby
    2.
    发明授权
    Process for physicochemically producing glycogen and glycogen obtained thereby 有权
    由此获得的物理化学产生糖原和糖原的方法

    公开(公告)号:US07396543B2

    公开(公告)日:2008-07-08

    申请号:US10497694

    申请日:2002-12-06

    IPC分类号: A61K36/00 A61K36/258

    CPC分类号: C08B37/0009

    摘要: A method of producing glycogen is provided. The method comprises the step of heat- and pressure-treating a sugar-containing material under acidic conditions. The sugar-containing material is a polysaccharide or an oligosaccharide. Alternatively, the sugar-containing material is a plant material selected from the group consisting of Panax notoginseng, Yun Nan San-chi powder (trademark), Panax ginseng, wheat flour, soybean, soy flour, shiitake, and coffee extract residue. Representatively, the glycogen includes a molecule having a molecular weight of 10,000 or less. The glycogen has a specific rotation of [α]D+197° and anomeric proton peaks at 5.37 ppm and 4.95 to 5.33 ppm in 1H NMR spectra.

    摘要翻译: 提供了制备糖原的方法。 该方法包括在酸性条件下对含糖材料进行加热和加压处理的步骤。 含糖材料是多糖或寡糖。 或者,含糖材料是选自三七,云南三奇粉(商标),人参,小麦粉,大豆,大豆粉,香菇和咖啡提取物残渣的植物材料。 代表性地,糖原包括分子量为10,000以下的分子。 在1 H NMR光谱中,糖原具有α-D + 197°的比旋光度和5.37ppm和4.95- 5.33ppm的异质质子峰。

    Process for physicochemically producing glycogen and glycogen obtained thereby
    3.
    发明申请
    Process for physicochemically producing glycogen and glycogen obtained thereby 有权
    由此获得的物理化学产生糖原和糖原的方法

    公开(公告)号:US20050048142A1

    公开(公告)日:2005-03-03

    申请号:US10497694

    申请日:2002-12-06

    CPC分类号: C08B37/0009

    摘要: A method of producing glycogen is provided. The method comprises the step of heat- and pressure-treating a sugar-containing material under acidic conditions. The sugar-containing material is a polysaccharide or an oligosaccharide. Alternatively, the sugar-containing material is a plant material selected from the group consisting of Panax notoginseng, Yun Nan San-chi powder (trademark), Panax ginseng, wheat flour, soybean, soy flour, shiitake, and coffee extract residue. Representatively, the glycogen includes a molecule having a molecular weight of 10,000 or less. The glycogen has a specific rotation of [α]D+197° and anomeric proton peaks at 5.37 ppm and 4.95 to 5.33 ppm in 1H NMR spectra.

    摘要翻译: 提供了制备糖原的方法。 该方法包括在酸性条件下对含糖材料进行加热和加压处理的步骤。 含糖材料是多糖或寡糖。 或者,含糖材料是选自三七,云南三奇粉(商标),人参,小麦粉,大豆,大豆粉,香菇和咖啡提取物残渣的植物材料。 代表性地,糖原包括分子量为10,000以下的分子。 在1 H NMR光谱中,糖原具有αD+ 197°的比旋光度和5.37ppm和4.95-5.33ppm的异质质子峰。

    Pyrroloazepine derivative
    5.
    发明授权
    Pyrroloazepine derivative 失效
    吡咯并氮衍生物

    公开(公告)号:US5397780A

    公开(公告)日:1995-03-14

    申请号:US30268

    申请日:1993-04-06

    IPC分类号: C07D487/04 A61K31/55

    CPC分类号: C07D487/04

    摘要: This invention provides a pyrroloazepine derivative represented by the following formula (I): ##STR1## where the substituents are defined in the specification. The pyrroloazepine derivatives according to the present invention are drugs having excellent anti-.alpha..sub.1 action and anti-serotonin action and feature high safety. They can therefore be used, for example, as novel therapeutics for circulatory diseases.

    摘要翻译: PCT No.PCT / JP92 / 01008 Sec。 371日期:1993年4月6日 102(e)日期1993年4月6日PCT提交1992年8月6日PCT公布。 出版物WO87 / 07274 日本1987年12月3日。本发明提供由下式(I)表示的吡咯并氮衍生物:在说明书中。 根据本发明的吡咯并氮衍生物是具有优异的抗α1作用和抗5-羟色胺作用并且具有高安全性的药物。 因此,它们可以用作例如循环系统疾病的新疗法。

    Pyrroloazepine compound
    6.
    发明授权
    Pyrroloazepine compound 失效
    吡罗沙星化合物

    公开(公告)号:US5399557A

    公开(公告)日:1995-03-21

    申请号:US30427

    申请日:1993-04-07

    IPC分类号: C07D487/04 A61K31/55

    CPC分类号: C07D487/04

    摘要: This invention provides a pyrroloazepine compound represented by the following formula (I) or (II): ##STR1## wherein Z.sub.1, Z.sub.2, R, A and Y are defined in the claims. The pyrroloazepine compounds according to the present invention are drugs having excellent anti-serotonin action. Coupled with their high safety, they can therefore be used as novel therapeutics for ischemic heart diseases. In addition, the compounds of the present invention include those having anti-.alpha..sub.1 action. Such compounds are effective as hypotensive drugs. Pyrroloazepine compounds according to the present invention are therefore extremely useful as therapeutics for a wide variety of circulatory diseases.

    摘要翻译: PCT No.PCT / JP92 / 01009 Sec。 371日期:1993年4月7日 102(e)日期1993年4月7日PCT提交1992年8月6日PCT公布。 公开号WO93 / 03032 日本特开昭通1 9 9 3年2月18日。本发明提供由下式(I)或(II)表示的吡咯并氮杂化合物:其中Z1,Z2,R,A和Y定义 在权利要求中。 根据本发明的吡咯并氮吡啶化合物是具有优异的抗5-羟色胺作用的药物。 结合高安全性,因此可用作缺血性心脏病的新疗法。 此外,本发明的化合物包括具有抗α1作用的化合物。 这些化合物作为降压药有效。 因此,根据本发明的吡罗洛西泮化合物作为多种循环系统疾病的治疗剂非常有用。

    Pyrroloazepine derivatives
    8.
    发明授权
    Pyrroloazepine derivatives 失效
    吡咯并氮衍生物

    公开(公告)号:US5391731A

    公开(公告)日:1995-02-21

    申请号:US987703

    申请日:1992-12-09

    CPC分类号: C07D487/04

    摘要: Disclosed herein are pyrroloazepine derivatives, which are useful as therapeutics for circulatory diseases, represented by the following formula (I): ##STR1## wherein R means a hydrogen atom, a linear or branched C.sub.1-6 alkyl group or a C.sub.7-10 aralkyl group, A denotes a linear or branched C.sub.2-10 alkylene, alkenylene or alkynylene group, Z stands for O, NOR.sub.1 or NOCOR.sub.5 in which R.sub.1 and R.sub.5 is a hydrogen atom or an alkyl, aryl or aralkyl group, and Y means a particular piperidinyl or pyrrolidinyl group; and salts thereof. Their preparation processes are also disclosed.

    摘要翻译: 本文公开了吡咯并氮嘌呤衍生物,其可用作由下式(I)表示的循环系统疾病的治疗剂:直链或支链C 1-6烷基或C 7-10芳烷基,A表示直链或支链C 2-10 亚烷基,亚烯基或亚炔基,Z代表O,NOR1或NOCOR5,其中R1和R5是氢原子或烷基,芳基或芳烷基,Y表示特定的哌啶基或吡咯烷基; 及其盐。 还公开了它们的制备方法。

    Pyrroloazepine derivatives
    9.
    发明授权
    Pyrroloazepine derivatives 失效
    吡咯并氮衍生物

    公开(公告)号:US5416082A

    公开(公告)日:1995-05-16

    申请号:US195019

    申请日:1994-02-14

    CPC分类号: C07D487/04

    摘要: Disclosed herein are pyrroloazepine derivatives having anti-.alpha..sub.1 activity and anti-serotonin activity represented by the following formula (I): ##STR1## wherein R means a hydrogen atom, a linear or branched C.sub.1-6 alkyl group or a C.sub.7-10 aralkyl group, A denotes a linear or branched C.sub.2-10 alkylene, alkenylene or alkynylene group, Z stands for O, NOR.sub.1 or NOCOR.sub.5 in which R.sub.1 and R.sub.5 is a hydrogen atom or an alkyl, aryl or aralkyl group, and Y means a particular piperidinyl or pyrrolidinyl group; and salts thereof. Their preparation processes are also disclosed.

    摘要翻译: 本文公开了具有由下式(I)表示的抗α1活性和抗5-羟色胺活性的吡咯并氮衍生物:直链或支链C 1-6烷基或C 7-10芳烷基,A表示直链或支链C 2-10 亚烷基,亚烯基或亚炔基,Z代表O,NOR1或NOCOR5,其中R1和R5是氢原子或烷基,芳基或芳烷基,Y表示特定的哌啶基或吡咯烷基; 及其盐。 还公开了它们的制备方法。